Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Five-fraction SBRT was noninferior to control radiotherapy with respect to biochemical or clinical failure and may be an efficacious treatment option for patients with low-to-intermediate-risk localized prostate cancer as defined in this trial. (Funded by Accuray and others; PACE-B ClinicalTrials.gov number, NCT01584258.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2024-10-16
DOI
https://doi.org/10.1056/nejmoa2403365
Citations
183
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
76.66

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Paula Wells, Nicholas van As, Alexander Martin, Emily Williamson et al.
183 citations
New England Journal of Medicine
Prostate Cancer Diagnosis and Treatment
76.66
article

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Paula Wells, Nicholas van As, Alexander Martin, Emily Williamson, Derek Price, Daniel Ford, Jaymini Patel, Peter Ostler, John Staffurth, Clare Griffin, Alison Tree, Stephanie Brown, Stephanie Burnett, Shaun Tolan, Julia Pugh, Emma Hall, Olivia Naismith, Philip Camilleri, H. van der Voet, Kiran Kancherla, Georgina Manning, Ian S. Dayes, Andrew K. Chan, William Chu, John Armstrong, J. Frew, Andrew Loblaw, Suneil Jain
article en
183 citations

Abstract

Five-fraction SBRT was noninferior to control radiotherapy with respect to biochemical or clinical failure and may be an efficacious treatment option for patients with low-to-intermediate-risk localized prostate cancer as defined in this trial. (Funded by Accuray and others; PACE-B ClinicalTrials.gov number, NCT01584258.).

New England Journal of MedicineVol. 391(15)
Cancer Research UK (GB)
Royal Marsden NHS Foundation Trust, Accuray, Prostate Cancer Canada, Cancer Research UK, National Institute for Health and Care Research
Good health and well-being
Openalex Percentile: Top 0%
Prostate Cancer Diagnosis and Treatment
76.66
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.